IL18 and melanoma: The initial findings from the enzyme-linked immunosorbent assay (ELISA) indicated a statistically significant downregulation of pyroptosis protein expression in melanoma patients when compared to the control group (Fig. 2C), especially NLRP1, GZMA, and GSDMB, followed by CHMP4A and IL18.